Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0WTBDK
ADC Name	huFR1-21-PEG4-Mal-DM1
Synonyms	huFR1 21 PEG4 Mal DM1 Click to Show/Hide
Organization	ImmunoGen, Inc.
Drug Status	Investigative
Indication	In total 2 Indication(s) Cervical cancer [ICD11:2C77] Investigative Ovarian cancer [ICD11:2C73] Investigative
Drug-to-Antibody Ratio	3.5-4
Structure
	3D MOL	2D MOL
Antibody Name	huFR1-21		Antibody Info
Antigen Name	Folate receptor alpha (FOLR1)		Antigen Info
Payload Name	Mertansine DM1		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	PEG4-Mal		Linker Info
Conjugate Type	Random conjugation through nucleophilic lysines.

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	1.00-10.00	nM	KB cells	Human papillomavirus-related endocervical adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	1.00-10.00	nM	KB cells	Human papillomavirus-related endocervical adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.00 nM-10.00 nM	Positive FOLR1 expression (FOLR1 +++/++)
Method Description	A PEG4-mal-DM4 conjugate in various concentrations was added to FOLR1-expressing KB cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium. Antibodies and conjugates were diluted into complete RPMI medium using 3-fold dilution seriesand 100 pL were added per well.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.00 nM-10.00 nM	Positive FOLR1 expression (FOLR1 +++/++)
Method Description	A PEG4-mal-DM4 conjugate in various concentrations was added to FOLR1-expressing KB cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium. Antibodies and conjugates were diluted into complete RPMI medium using 3-fold dilution seriesand 100 pL were added per well.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

References

Ref 1	Folate receptor 1 antibodies and immunoconjugates and uses thereof; 2011-09-01.